Mavacamten in oHCM: Q&A with Cardiology Specialist, Lynn Cronin, MD

Dr. Cronin provides her perspectives on identification, treatment, and management of oHCM patients using the novel cardiac myosin inhibitor, mavacamten. Lynn Cronin, MD, FACC is board-certified in cardiology with clinical interests in adult congenital heart disease, valvular heart disease, and chronic ischemic heart disease. She is affiliated with multiple hospitals in the Holland, MI area including Spectrum Health.